Innovative Report on Anti-AIDs Drug Market with Competitive Analysis and Top Key Companies (GSK, Cipla, MSD, Gilead Sciences) | Forecasts 2020-2025

A market study ”Global Anti-AIDs Drug Market” examines the performance of the Global Anti-AIDs Drug Market 2020. It encloses an in-depth Research of the Anti-AIDs Drug Market state and the competitive landscape globally. This report analyzes the potential of Anti-AIDs Drug Market in the present and the future prospects from various angles in detail.

Global Anti-AIDs Drug Market Overview:

The report spread across 90 pages is an overview of the Global Anti-AIDs Drug Market Report 2020. The Global Anti-AIDs Drug Market is projected to grow at a healthy growth rate from 2020 to 2025 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.

The major factors driving the growth of the Global Anti-AIDs Drug Market are rapid growth in prevalence of HIV and increase in treatment & diagnosis rate. In addition, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/275342 .

The Global Anti-AIDs Drug Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Anti-AIDs Drug Market is sub-segmented into Prescription Drugs, Non-prescription Drugs and others. On the basis of Application, the Global Anti-AIDs Drug Market is classified into Pharmacy, Hospital and others.

In terms of the geographic analysis, The Anti-AIDs Drug Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Anti-AIDs Drug Market ecosystem results in the increasing adoption of these systems in North America.

Medical Industry News:

GSK (October 05, 2020) - ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress. Findings showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine continued to offer non-inferior efficacy, a high genetic barrier to resistance and a comparable safety profile versus a 3-drug regimen of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-naïve adults with HIV-1.

Pedro Cahn, M.D., Scientific Director, Fundacion Huesped, Professor of Infectious Diseases, Buenos Aires University Medical School, and principal investigator for the GEMINI study programme, said: “These long-term data confirm that dolutegravir-based 2-drug regimens have a rightful place in the HIV treatment compendium. Dolutegravir plus lamivudine continues to demonstrate long-term non-inferior efficacy compared to dolutegravir plus TDF/FTC with benefits beyond viral suppression. While overall adverse event rates were similar across the study arms, we saw fewer drug-related adverse events with dolutegravir plus lamivudine. Clinicians who wanted proof that a dolutegravir-based 2-drug regimen works long-term in treatment-naïve adults with HIV now have evidence to show that it does.”       

A pooled analysis of the two studies showed that dolutegravir plus lamivudine demonstrated non-inferiority, with 82% (584/716) of participants in the Snapshot analysis – Intention to Treat-Exposed (ITT-E) population having HIV-1 RNA less than 50 copies per millilitre (c/mL) at Week 144, compared with 84% (599/717) of participants receiving a 3-drug regimen of dolutegravir plus TDF/FTC (adjusted difference: -1.8 [95% CI: -5.8%, 2.1%]).[1] Safety and tolerability findings were consistent with previous data.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Anti-AIDs Drug Market Report 2020” @ https://www.businessindustryreports.com/buy-now/275342/single .

Top Leading Key in Players Global Anti-AIDs Drug Market: GSK, Cipla, MSD, Gilead Sciences, Frontier Biotechnologies and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

With the presence of a large pool of participants, the Global Anti-AIDs Drug Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). GSK, Cipla, MSD, Gilead Sciences, Frontier Biotechnologies are some of the key vendors of Anti-AIDs Drug across the world. These players across Anti-AIDs Drug Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.

Region segment: Anti-AIDs Drug Market report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Anti-AIDs Drug in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/275342 .

Major Points in Table of Contents:

Global Anti-AIDs Drug Market Report 2020

1 Anti-AIDs Drug Product Definition

2 Global Anti-AIDs Drug Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Anti-AIDs Drug Shipments

2.2 Global Manufacturer Anti-AIDs Drug Business Revenue

2.3 Global Anti-AIDs Drug Market Overview

2.4 COVID-19 Impact on Anti-AIDs Drug Industry

3 Manufacturer Anti-AIDs Drug Business Introduction

3.1 GSK Anti-AIDs Drug Business Introduction

3.2 Cipla Anti-AIDs Drug Business Introduction

3.3 MSD Anti-AIDs Drug Business Introduction

3.4 Gilead Sciences Anti-AIDs Drug Business Introduction

3.5 Frontier Biotechnologies Anti-AIDs Drug Business Introduction

………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.